Molecular Characterization of Staphylococcus aureus Obtained from Blood Cultures of Paediatric Patients Treated in a Tertiary Care Hospital in Mexico

Guillermo Jose Vazquez-Rosas 3,1,2 Jocelin Merida-Vieyra 3 Gerardo Aparicio-Ozores 3,2 Antonio Lara-Hernandez 3 Agustin De Colsa 2,1,4 Alejandra Aquino-Andrade 1,4

1Molecular Microbiology Laboratory, Instituto Nacional de Pediatría, Mexico City, Mexico; 2Medical Bacteriology Laboratory, Instituto Politécnico Nacional, Mexico City, Mexico; 3Bacteriology Laboratory, Instituto Nacional de Pediatría, Mexico City, Mexico; 4Department of Paediatric Infectious Diseases, Instituto Nacional de Pediatría, Mexico City, Mexico

Purpose: Staphylococcus aureus is one of the main causative agents of hospital-acquired (HA) infections. In Mexico, information about the characteristics of clinical S. aureus isolates is limited. Our aim was to characterize S. aureus strains obtained from blood cultures of paediatric patients treated in a tertiary care hospital.

Materials and Methods: We analysed 249 S. aureus isolates over the period from 2006 to 2019, and their resistance profiles were determined. The isolates were classified into methicillin-resistant S. aureus (MRSA) or methicillin-sensitive S. aureus (MSSA). Staphylococcal cassettes chromosome mec (SCCmec) were detected. Virulence genes (cna, clfA, clfB, eta, eth, fnbA, fnbB, hla, pvl, sec, and tss) were amplified, and their clonal relationships were established by pulsed-field gel electrophoresis (PFGE), multilocus sequence typing (MLST) and clonal complex (CC) typing. We reviewed one hundred medical files to collect clinical information.

Results: Thirty-eight percent of the isolates were MRSA and showed an expanded profile of resistance to other non-beta-lactam antibiotics, while MSSA strains presented a reduced resistance profile. SCCmec-II was the most frequent element (86.3%). Eight virulence factors were detected in MSSA and six in MRSA. The pvl gene was detected in four MRSA-SCCmec-IV isolates (P≤0.0001). MRSA isolates were distributed among 14 clones and were classified into 15 sequence types (ST); the most frequent was ST1011 (17%). The most common CC in MRSA was CC5 (69%, P≤0.0001), and in MSSA, it was CC30 (30%, P≤0.0001). Eighty-seven percent of MRSA isolates were HA-MRSA, and 13% were community-acquired MRSA (CA-MRSA). Of 21 HA-MRSA isolates, 17 had SCCmec-II, while two CA-MRSA isolates had SCCmec-IV. Of MSSA isolates, 77% were derived from HA infections and 23% from CA infections.

Conclusion: MSSA isolates had more virulence factors. MRSA isolates were resistant to more non-beta-lactam antibiotics, and those with SCCmec-IV expressed a greater variety of virulence factors. Most S. aureus isolates belonged to CC5.

Keywords: MSSA, MRSA, virulence factors, clonal complex, SCCmec-II, CC5

Introduction
Among Gram-positive bacteria, Staphylococcus aureus is the main causative agent of hospital-acquired (HA) and community-acquired (CA) infections. S. aureus can cause mild skin and soft tissue infections and severe infections, including bacteremia, sepsis, endocarditis, and osteomyelitis. 1 One of the main challenges in the treatment of these infections is antibiotic resistance. Although the worldwide average prevalence of MRSA is 40%, 2 there are vast differences among different...
geographical locations: in Latin America, the reported prevalence is between 6–80%; in Mexico, 52–57%; in China, 50%; and in Europe, 0.9–26.8%. Molecular characterization of *S. aureus* has become a tool for the investigation and detection of circulating and epidemic clones both in the hospital and in the community. These clones can be typed based on SCC*mec*, MLST, CC, PFGE and the presence of virulence factors, namely, Panton–Valentine leukocidin (PVL). HA infections are associated with MRSA clones with SCC*mec* elements I, II and IV of ST5 and CC5.

In Mexico, there is limited information about the molecular characteristics of MRSA associated with bacteraemia in paediatric patients. Some studies have analysed infections caused by *S. aureus* and comorbidities, such as cancer, and their clinical implications and have also classified the isolates based on their susceptibility profiles. In a tertiary care adult hospital, 444 linezolid (LZD)- and vancomycin (VAN)-sensitive MRSA isolates were studied; all had SCC*mec*-II. In a report from Latin America, 538 MRSA isolates were typed; 17 isolates from a single hospital in Mexico had SCC*mec*-II and were classified as USA100 and ST5. Our aim was to characterize 249 *S. aureus* isolates obtained from blood cultures of paediatric patients treated in a tertiary care hospital over a 14-year period.

**Materials and Methods**

**Study Setting**

Our study was conducted at the Instituto Nacional de Pediatría (INP), which is a tertiary care paediatric hospital with 235 beds, 40 subspecialities and 6981 discharges in 2017.

**Biological Material**

A total of 249 nonduplicate *S. aureus* isolates obtained from blood cultures of paediatric patients (0 to <18 year-old) with documented bacteraemia from 2006 to 2019 were analysed. The distribution of the isolates by year was as follows: 2006 (n=24), 2007 (n=24), 2008 (n=24), 2009 (n=21), 2010 (n=23), 2011 (n=22), 2012 (n=15), 2013 (n=21), 2014 (n=15), 2015 (n=35), 2016 (n=21), 2018 (n=2), and 2019 (n=2). In 2017, we did not obtain any *S. aureus* isolates. We defined bacteraemia as positive peripheral blood cultures obtained from a patient with signs and symptoms of infection.

**Identification**

The isolates were identified using a BD Phoenix semi-automated microbiology system (Becton Dickinson, Franklin Lakes, New Jersey, USA). DNA extraction was performed with the QIAamp DNA mini® kit (Qiagen, Hilden, North Rhine-Westphalia, Germany). The DNA was eluted and stored at −20 °C until use. Identification as *S. aureus* was corroborated by detection of the *nuc* gene and by amplification, sequencing, and analysis of the 16S rRNA gene. AmpliTaq Gold® 360 Master Mix (Applied Biosystems™, Foster City, California, USA) was used in all the reaction mixtures.

**Resistance Profile**

A disk diffusion test was performed for cefoxitin (FOX), gentamicin (GEN), ciprofloxacin (CIP), clindamycin (CLI), erythromycin (ERI), trimethoprim with sulfamethoxazole (SXT) and LZD using sensidiscs (Becton Dickinson, Franklin Lakes, Nueva Jersey, USA), and a broth microdilution test was performed for FOX (Sigma Aldrich, St. Louis, Missouri, USA) following the 2019 guidelines of the Clinical and Laboratory Standards Institute (CLSI).

**Molecular Characterization of MRSA Isolates**

The presence of the *femA* and *mecA* genes was confirmed by PCR. Detection of the *vanA* gene was also performed. SCC*mec* elements were identified by multiplex PCR (mPCR). The presence of genes encoding virulence factors necessary for colonization (*fnbA*, *fnbB*, *clfA*, *clfB* and *cna*), invasion (*hla* and *pvl*), toxins (*sec*, *eta* and *etb*), and superantigen (*iss* or *lst*) was detected. The GeneAmp® PCR System 9700 was used for all PCRs (Applied Biosystems™, Foster City, California, USA). We used *S. aureus* ATCC® 43300™ and *Enterococcus faecium* ATCC® 29212™ as positive controls.

PFGE typing was performed using the CHEF Mapper XA System (Bio-Rad, Hercules, California, USA) following the guidelines established in the PulseNet protocol for MRSA from the Centers for Disease Control and Prevention. Analysis of clonal relationships was carried out using the Tenover criteria. A dendrogram was constructed using the program DendroUPGMA. ST detection was performed by MLST. The sequences obtained were compared with those reported in the *S. aureus* MLST online database from the
University of Oxford. The six most widely distributed CCs were determined using mPCR.

Clinical Data
We reviewed the medical files to collect clinical information, such as age, sex, comorbidity, primary infectious focus (PIF), clinical complications, outcome, length of hospital stay, and antibiotic treatment. An infection was considered HA if the date of the event of the site-specific infection criterion occurred on or after the 3rd calendar day of admission to an inpatient location where the day of admission was calendar day 1. We categorized the age as follows: term neonatal (birth-27 days), infant (28 days-12 months), toddler (13 months-2 years of age), early childhood (2-5 years of age), middle childhood (6-11 years of age), and early adolescence (12-<18 years of age). To standardize the duration of treatment in all cases, the day of blood culture collection was taken as day zero.

Statistical Analysis
We compared the overall group infected with MRSA and those infected with MSSA. JPM 11 software (SAS Institute Inc., Cary, NC, USA) was used. The variables were described as frequencies and percentages. Categorical variables were compared using Pearson’s χ² test. A value of P<0.05 was considered statistically significant.

Results
Detection of the nuc, 16S rRNA, femA, mecA and vanA Genes and Identification of the SCCmec Elements
The nuc gene was amplified from 245 isolates, while the 16S rRNA gene was sequenced from four isolates, confirming the 249 isolates as S. aureus. The femA gene was detected in 176 (70.6%) isolates: 91 were MSSA and 85 were MRSA.

The vanA gene was not detected in any isolate. The mecA gene was amplified in 95 isolates (38.1%), and these isolates were classified as MRSA. Three different SCCmec elements were found: SCCmec-I (3.1%, n=3), SCCmec-II (86.3%, n=82), and SCCmec-IV (9.4%, n=9). In one isolate, it was not possible to determine the SCCmec element with the primers used in this study (Figure 1). Over the years, the MRSA isolates decreased in frequency, while the MSSA isolates increased (Figure 2).

Susceptibility Profile
The 95 MRSA isolates presented the following susceptibility profile: GEN 88.4% (n=84), CIP 5.2% (n=5), ERI 4.2% (n=4), CLI 8.4% (n=8), and SXT 92.6% (n=88); all the isolates were sensitive to LZD. In the 154 isolates classified as MSSA, the following susceptibility profile was obtained: GEN 96% (n=148), CIP 89% (n=138), ERI 57% (n=92), CLI 74% (n=123), SXT 98% (n=152), and LZD 100% (n=154). Twenty-two MSSA isolates with inducible resistance to CLI were detected (Table 1). ERI, CIP and CLI resistance was observed in the MRSA isolates (P≤0.0001).

Virulence Profile
A gene that promotes colonization (fnbA) and a gene that favours invasion (hla) were the most frequently observed virulence genes. Only four MRSA isolates had the pvl gene in which SCCmec-IV was detected (Table 2). The clfA and clfB genes were not detected in any isolate. The pvl gene was more frequent in the MRSA SCCmec-IV (P≤0.0001).

Determination of Clonality
The 95 MRSA isolates were distributed among 14 clones by PFGE and were assigned letters A to N; 50% of these isolates were grouped into clones A B and C and contained SCCmec-II. Fifteen STs were determined to be distributed among all clones, the most frequent being ST1011 (17%, n=4), ST5 (13%, n=3) and ST5529 (13%, n=3). MRSA-SCCmec-IV belonged to ST8, ST4335, ST544, ST1092, ST4732 and ST30, and the pvl gene was amplified in only two ST4335 isolates. Among the total isolates, six CCs were detected, which were distributed as follows: 44.9% (n=112) CC5, 19.6% (n=49) CC30, 10.8% (n=27) CC45, 5.2% (n=13) CC8, 1.6% (n=4) CC22, and 0.8% (n=2) CC1. CCs were not identified in 42 (16.8%) S. aureus isolates.

The MRSA isolates (n=95) were grouped mainly into CC5 69.4% (n=66), CC8 8.4% (n=8), CC45 4.2% (n=4), CC30 2.1% (n=2), and CC22 1% (n=1); the type of CC was not classified in 14.7% (n=14) of the isolates (Figure 3). CC5 was statistically significant in the MRSA isolates (P≤0.0001). The 154 MSSA isolates could not be classified into clones since they presented a great diversity of patterns obtained by PFGE, and the distribution of their CCs was different; CC30 was the most common with 30.5% (n=47), followed by CC5 with 29.8% (n=46),
CC45 with 14.9% (n=23), CC8 with 3.2% (n=5), CC22 with 1.9% (n=3), and CC1 with 1.2% (n=2). CCs could not be identified in 18.1% (n=28) of the MSSA isolates. CC30 was statistically significant in the MSSA isolates ($P \leq 0.0001$).

Clinical Data

Of the 249 S. aureus isolates, clinical information was obtained for 100 of the patients from whom they were isolated. Twenty-four isolates were MRSA and 76 were MSSA. Seventy-nine percent of the patients with MRSA infections presented with comorbidities; among the most important of which were oncological diseases (16%, n=4), nephropathies (16%, n=4), and neuropathies (16%, n=4). Central venous catheter (CVC) was identified as the main PIF (66%, n=16). Eighty-seven percent (n=21) of the infections were HA-MRSA, and 13% (n=3) were CA-MRSA. Forty-five percent (n=11) of the patients presented with complications derived from the infection and sepsis was the main complication, with 82% (n=9), followed by septic shock, with 18% (n=2). Twelve percent (n=3) of the patients died, and two deaths were related to the infection. The definitive treatment for infections caused by MRSA was VAN (79%, n=19), followed by teicoplanin (TEC) with 20% (n=5) (Table 3).

On the other hand, of the 76 patients with infections caused by MSSA, 81% (n=62) had a comorbidity, and the most frequent were oncological diseases, with 51% (n=33). As in MRSA, a CVC was the main source of infection (47%, n=36). Seventy-seven percent (n=58) were HA-MSSA, and 23% (n=18) were CA-MSSA. Thirty-eight percent (n=27) of the patients presented with

Figure 1 Distribution of SCCmec by year. A predominance of SCCmec-II was observed from 2006 to 2013 and in 2015. The first occurrence of SCCmec-IV was detected in 2007.
Discussion

This study describes the main characteristics of a collection of *S. aureus* isolates obtained from blood cultures over 14 years in a tertiary care paediatric hospital in Mexico; 38.1% of these isolates were MRSA. The average frequency of MRSA worldwide is 40%, but this frequency can vary among different regions. In the US, the frequencies of infections caused by MRSA range from 23.7–45%; in Europe, 0.9–26.8%; in Asia, 39.6–56.6%; in Latin America, 6–80%; and in Mexico, a frequency of 52–57% has been reported. A decrease in the frequency of MRSA worldwide from 45–40% has been observed, which may be due to different factors, for instance, the type of hospital, the origin of the isolates and the patient characteristics. In addition, this decrease may be related to the implementation of surveillance programmes that in some countries are very well structured, including the search and destroy policy of carriers in the Netherlands, the enhanced mandatory surveillance programme in the United Kingdom, and the nationwide MRSA Prevention Initiative in the U.S. However, there is not enough evidence to suggest that these programmes are solely responsible for this phenomenon. The common factor among the different studies is that control measures should always be accompanied by a programme for compliance with hand hygiene. Increases in the hospital frequency of MRSA could be related to the presence of outbreaks, such as the event that occurred in a cancer hospital in Mexico, where an increase in MRSA isolates from 4–20.4% was observed in 2014 due to an outbreak, which was controlled by a programme that reinforced hand hygiene.

In our study, a decrease in the frequency of MRSA was observed in recent years (2011–2019). It is important to mention that this could be the result of the implementation of a permanent monitoring programme for adequate handwashing in 2013. However, there is no surveillance and eradication programme for carriers of this pathogen.

The decrease in the frequency of MRSA and the increase in MSSA, as well as other *Staphylococcus* spp. that are causative agents of bacteraemia, has been associated with a greater diversity of virulence factors in these groups, favouring colonization and invasion. Our study focused on isolates from blood cultures of paediatric patients, and we observed a decrease in the presentation of complications derived from the infection, and sepsis was the main complication, with 58% (n=17), followed by septic shock, 20% (n=6). Thirteen percent (n=10) of the patients died; two deaths were associated with the infection. The definitive treatment for infections caused by MSSA was dicloxacillin (DC) in 61% (n=47), followed by VAN in 52% (n=40) and ceftriaxone (CRO) in 27% (n=21) (see Supplementary material).
MRSA, similar to the global trend, so it is important to continue studying and monitoring this pathogen.

The treatment of choice for MRSA infections should focus on the susceptibility profile, age group, PIF and comorbidities. Although resistance to beta-lactams in S. aureus, which is mediated by mecA, limits some therapeutic options, it has been observed in different studies that there are still alternatives for the treatment of bacteremia, such as LZD, daptomycin (DAP) and SXT. Our results also indicate that there is a high susceptibility to antibiotics, including oxazolidinones (LZD 100%) folate inhibitors (SXT 96.3%) and glycopeptides (VAN 100%). In turn, MRSA remains susceptible to lincosamides, which are second-line treatments for MRSA, at levels close to 50% of susceptibility. Although VAN is the first-choice antimicrobial for MRSA bacteraemia, there are other treatment alternatives, such as LZD, SXT and CLI, in monotherapy or in combination with DAP or ceftaroline (CPT). Therefore, interpretive reading of the antibiograms and the usage of first-choice antimicrobials are essential to reduce the risk of therapeutic failure and increase resistance rates.

The SCCmec elements allow to classify the MRSA strains into HA and CA. A change was observed in the distribution of the SCCmec elements in our hospital. Type II decreased, while type IV was detected more frequently in recent years. In some regions of the world, there has been a decrease in cassettes I, II and III, historically associated with HA infections, and an increase in cassettes IV and V (associated with CA infections). This exchange has been widely described in the U.S., Iran and South Africa.

Currently, the detection of SCCmec elements and their classification is not sufficient to determine the best treatment, since the search for virulence factors is also important. In several studies, MRSA isolates have a greater variety of virulence genes, among which the presence of pvl, tsst and sea stand out, and these are mainly associated with MRSA isolates with SCCmec–IV.

The frequency of pvl in MRSA varies from 9–30%; in Iran (9.7%), South Africa (14%), the US (26%), and China (30%). In the current study, we found the pvl gene in four isolates (1.6%), all with SCCmec–IV. In 2016, the first MRSA SCCmec–IV isolate with pvl was detected. It is important to monitor the change in the distribution of SCCmec elements because in other countries, in particular the US, MRSA SCCmec–IV isolates reach 28%, China 61%, South Africa 48% and Japan 52.3%. PVL is...
one of the main virulence factors that complicate the clinical features and the therapeutic approach, since prolonged treatment of MRSA infections, producing this toxin, with VAN can lead to therapeutic failure, so it is necessary to use combinations, such as LZD and CLI, to inhibit the production of PVL.57,58

Table 2 Virulence Profile of S. aureus Isolates

| Isolates         | Colonization | Invasion | Toxins | Superantigen |
|------------------|--------------|----------|--------|--------------|
|                  | fnbA (%)     | fnbB (%) | cna (%) | hla (%) | pvl (%) | sec (%) | eta (%) | etb (%) | tsst (%) |
| S. aureus n=249  | 207(83.1)    | 18(7.2)  | 16(6.4) | 186(74.6)| 4(1.6)  | 7(2.8)  | 5(2)    | 1(0.4)  | 38(15.2) |
| MSSA n=154       | 135(54.2)    | 11(4.4)  | 16(6.4) | 113(45.3)| 0       | 6(2.4)  | 5(2)    | 1(0.4)  | 37(14.8) |
| MRSA n=95        | 72(28.9)     | 7(2.8)   | 0       | 73(29.3)| 4(1.6)  | 1(0.4)  | 0       | 0       | 0        |
| SCCmec-I n=3     | 3(1.2)       | 2(0.8)   | 0       | 3(1.2)  | 0       | 0       | 0       | 0       | 0        |
| SCCmec-II n=82   | 63(25.3)     | 0        | 0       | 64(25.7)| 0       | 1(0.4)  | 0       | 0       | 0        |
| SCCmec-IV n=9    | 6(2.4)       | 5(2)     | 0       | 5(2)    | 4(1.6)  | 0       | 0       | 0       | 1(0.4)  |
| SCCmec-ND n=1    | 0            | 0        | 0       | 1(0.4)  | 0       | 0       | 0       | 0       | 0        |

Notes: None of isolates harbored clf A and clf B.
Abbreviations: MSSA, methicillin-sensitive Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; SCCmec, staphylococcal cassette chromosome mec; ND, not determined.
| Isolate | Age             | Sex | Year | SCC mec | Comorbidity          | PIF    | Acquired | Complication | Outcome | LHS | Treatment     |
|---------|-----------------|-----|------|---------|----------------------|--------|----------|--------------|---------|-----|---------------|
| Sa-125  | Toddler         | F   | 2011 | II      | Neurological disorder| CVC    | HA       | Sepsis       | Alive   | 105 |               |
| Sa-142  | Infant          | M   | 2011 | II      | Hematological disorder| CVC    | HA       | Sepsis       | Alive   | 30  |               |
| Sa-158  | Infant          | M   | 2012 | II      | Congenital disease   | CVC    | HA       | Sepsis       | Alive   | 42  |               |
| Sa-174  | Middle childhood| M   | 2013 | II      | Immunological disorder| CVC    | HA       | Sepsis       | Alive   | 86  |               |
| Sa-177  | Infant          | F   | 2013 | II      | Neurological disorder| CVC    | HA       | None         | Alive   | 101 |               |
| Sa-178  | Infant          | M   | 2013 | II      | Gastrointestinal disorder| CVC    | HA       | None         | Alive   | 53  |               |
| Sa-187  | Infant          | F   | 2013 | II      | Gastrointestinal disorder| CVC    | HA       | Sepsis       | Death   | 40  |               |
| Sa-189  | Early adolescence| M | 2013 | IV     | Nephropathy          | CVC    | HA       | Sepsis       | Alive   | 9   | + to +7        |
| Sa-190  | Infant          | M   | 2013 | III     | Oncological disorder| CVC    | HA       | Sepsis       | Alive   | 64  | +2 to +5       |
| Sa-197  | Middle childhood| M   | 2014 | IV     | Hematological disorder| CVC    | HA       | Sepsis       | Alive   | 63  | -3 to +33      |
| Sa-206  | Early adolescence| F | 2014 | II     | Oncological disorder| CVC    | HA       | Sepsis       | Alive   | 31  | -3 to +10      |
| Sa-218  | Middle childhood| F   | 2015 | II     | Nephropathy          | OC     | HA       | None         | Alive   | 27  | +6 to +20      |
| Sa-221  | Middle childhood| F   | 2015 | II     | Nephropathy          | OC     | HA       | None         | Alive   | 27  | +1 to +15      |
| Sa-222  | Middle childhood| F   | 2015 | II     | Nephropathy          | OC     | HA       | None         | Alive   | 27  | +1 to +15      |
| Sa-226  | Infant          | M   | 2015 | II     | Oncological disorder| OC     | HA       | None         | Alive   | 33  | 0 to +14       |
| Sa-241  | Early childhood | M   | 2015 | II     | None                | Surgical wound| HA   | None         | Death   | 44  | 0 to +22       |
| Sa-249  | Early childhood | F   | 2015 | II     | Neurological disorder| CVC    | HA       | None         | Alive   | 26  | 0 to +13       |
| Sa-250  | Middle childhood| M   | 2015 | II     | Hematological disorder| CVC    | HA       | None         | Death   | 80  | -6 to +14      |
| Sa-252  | Toddler         | F   | 2015 | II     | Neurological disorder| CVC    | HA       | None         | Alive   | 164 | +2 to +23      |
| Sa-272  | Term neonatal   | F   | 2016 | IV     | None                | CVC    | HA       | None         | Alive   | 28  | +1 to +16      |
| Sa-276  | Early adolescence| M | 2018 | IV     | None                | Bones CA | Septic shock| Alive   | 44  | 0 to +9        |
| Sa-279  | Middle childhood| M   | 2018 | IV     | None                | SSTI CA | None       | Alive   | 7     | +2 to +44      |
The MSSA isolates showed a greater diversity of virulence factor genes compared to MRSA, and it has been shown that MSSA, by presenting a greater number of virulence genes and acquiring resistance to antibiotics such as macrolides and lincosamides, complicates the clinical management of patients.59

The MRSA isolates with SCCmec-IV were more susceptible to antibiotics and several virulence genes were found, among which pvl, fnbA and fnbB stand out. The SCCmec—II isolates mainly harbour invasion genes, such as hla and sec. It is important to determine the presence of virulence genes in isolates, regardless of whether they are MSSA or MRSA, since it allows for a better therapeutic approach and consideration of the possible clinical complications that the patient may experience, including fulminant pneumonia, endocarditis, or sepsis.57

The genetic characteristics of S. aureus have shown that each geographic region can have its own clonal distribution.60-62 This discrimination cannot be solely achieved with the PFGE method, and other tools such as MLST and CC typing are needed. According to several studies, CC5 is the main CC detected in the Americas and Asia.55,63-65 We observed the same trend, since of the 14 clones, 50% were grouped into CC5 (69%), followed by CC8 (8.4%). CC5 is more common in MRSA with SCCmec-II, and CC8 has been associated with MRSA-SCCmec-IV isolates with PVL, which leads to more serious clinical conditions, in particular fulminant pneumonia or deep vein thrombosis.58 In our study, 14.7% of the MRSA and 18% of the MSSA isolates could not be grouped into any CC because the method used only detected the six most common CCs distributed around the world.31 PFGE, MLST, CC, spa typing, SCCmec, CC, and virulence factor detection are methods used to determine the MRSA epidemiology, and this information can impact the treatments applied to patients. ST5 was one of the most common in our collection, which coincides with that reported in other Latin American countries, such as Brazil (89%) and Guatemala (95%), but differs from that reported in Colombia (79%) and Ecuador (72%), where ST8 occurs more frequently.5

To control the dispersion of MRSA in our hospital, we must implement a permanent surveillance programme to study its spread and continue to monitor the different genetic characteristics of MRSA.

**Conclusion**

The MRSA isolates were grouped into clones, while the MSSA did not have a clonal relationship; however, most
of the *S. aureus* isolates belonged to CC5, and the interpretation of the susceptibility profiles of the isolates showed that there are still first-line therapeutic options for the management of *S. aureus* infections in our hospital to control and prevent the emergence of new resistance strains.

MRSA was detected in 38.1% of the isolates from our hospital. The frequency of MRSA decreased over the years, while an increase in the number of MSSA was observed. SCCmec-II was the most common among the studied isolates; however, starting in 2016, the frequency of SCCmec-IV increased.

MRSA strains containing SCCmec-IV exhibited a greater variety of virulence genes related to colonization or invasion than those containing SCCmec-II. However, the *pvl* gene was only detected in 1.6% of the isolates.

**Abbreviations**

CA, Community-acquired; CA-MRSA, Community-acquired methicillin-resistant *Staphylococcus aureus*; CC, Clonal complex; CIP, Ciprofloxacin; CLI, Clindamycin; CLSI, Clinical and Laboratory Standards institute; CPT, Ceftaroline; CRO, Ceftiraxone; CVC, Central venous catheter; DAP, Daptomycin; DC, Dicloxacillin; ERI, Erythromycin; FOX, Cefoxitin; GEN, Gentamicin; HA, Hospital-acquired; HA-MRSA, Hospital-acquired methicillin-resistant *Staphylococcus aureus*; INP, Instituto Nacional de Pediatría; LHS, Length of hospital stay; LZD, Linezolid; MLST, Multilocus sequence typing; nPCR, Multiplex PCR; MRSA, Methicillin-resistant *Staphylococcus aureus*; MSSA, Methicillin-sensitive *Staphylococcus aureus*; PIF, Primary infectious focus; PFGE, Pulsed-field gel electrophoresis; PVL, Pantonal-Valentine leucocidin; SCCmec, Staphylococcal cassette chromosome mec; ST, Sequence type; SXT, Trimethoprim with sulfamethoxazole; TEC, Teicoplanin; VAN, Vancomycin.

**Data Sharing Statement**

We confirm the data patient were deidentified. All the data generated or analysed during this study are included in this published article.

**Ethics Approval and Informed Consent**

This study was approved by the research, ethics, and biosafety committees of Instituto Nacional de Pediatría (IRB: 00008064 and IRB: 00008065) under registration INP 2018/17. The ethics committee did not require informed consent because the samples obtained were part of the standard care for hospitalized patients, and the isolates were obtained retrospectively. The patient data were deidentified.

**Author Contributions**

All authors contributed to data analysis, drafting or revising the article, have agreed on the journal to which the article will be submitted, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

**Funding**

This study was supported by the National Council of Science and Technology (Consejo Nacional de Ciencia y Tecnología–CONACYT) through project FOSSIS-2017-1-289537; by the Instituto Politecnico Nacional through SIP 20202136 and by modality A funding resources INP-2019 and INP-2020 under registration INP-2018/017.

**Disclosure**

The authors declare that they have no competing interests.

**References**

1. Turner NA, Sharma-Kuinkel BK, Maskarinec SA, et al. Methicillin-resistant *Staphylococcus aureus*: an overview of basic and clinical research. Nat Rev Microbiol. 2019;17(4):203–2018. doi:10.1038/s41579-018-0147-4
2. Diekema DJ, Pfaller MA, Shortridge D, Zeros M, Jones RN. Twenty-year trends in antimicrobial susceptibilities among *Staphylococcus aureus* from the SENTRY antimicrobial surveillance program. Open Forum Infect Dis. 2019;6:547–553. doi:10.1093/ofid/ofy270
3. Arias CA, Reyes J, Carvalho LP, et al. A prospective cohort multicenter study of molecular epidemiology and phenogenetics of *Staphylococcus aureus* bacteremia in nine Latin American countries. Antimicrob Agents Chemother. 2017;61(10):e00816–17
4. Seas C, Garcia C, Salles MJ, et al. *Staphylococcus aureus* bloodstream infections in Latin America: results of a multinational prospective cohort study. J Antimicrob Chemother. 2019;73:212–222. doi:10.1093/jac/dkx350
5. Dai Y, Liu J, Guo W, et al. Decreasing methicillin-resistance *Staphylococcus aureus* (MRSA) infections is attributable to the disappearance of predominant MRSA ST239 clones, Shangai, 2008–2017. Emerg Microbes Infect. 2019;8:471–478. doi:10.1080/22221751.2019.1595161
6. Hassoun A, Linden PK, Friedman B. Incidence, prevalence and management of MRSA bacteremia across patient populations– a review of recent developments in MRSA management and treatment. Crit Care. 2017;21:211. doi:10.1186/s13054-017-1801-3
7. Li X, Huang T, Xu K, Li C, Li Y. Molecular characteristics and virulence gene profiles of *Staphylococcus aureus* isolates in Hainan, China. BMC Infect Dis. 2019;19:873. doi:10.1186/s12879-019-4547-5
8. Challagundla L, Reyes J, Rafiquillah I, et al. Phylogenetic classification and the evolution of clonal complex 5 methicillin-resistant *Staphylococcus aureus* in the western hemisphere. *Front Microbiol*. 2018;9:1901. doi:10.3389/fmicb.2018.01901

9. Velázquez-Acosta C, Cornejo-Juárez P, Volkow-Fernández P. Multidrug resistance E-ESKAPE strains isolated from blood cultures in patients with cancer. *Salud Publica Mex*. 2018;60:151–157. doi:10.21148/8767

10. Chacon-Cruz E, Rivas-Landeros RM, Volker-Soberanes ML, Lopatynsky-Reyes EZ, Becka C, Alvelais-Palacios JA. 12 years active surveillance for pediatric pleural empiema in a mexican hospital: effectiveness of pneumococcal 13-valent conjugate vaccine; and early emergence of methicillin-resistant *Staphylococcus aureus*. *Ther Adv Infect Dis*. 2019;6:2049936119839312.

11. Garza-García E, Morfín-Otero R, Mendoza-Olazarán S, et al. A Snapshot of antimicrobial resistance in Mexico. Results from 47 centers from 20 states during a six-month period. *PloS One*. 2019;14:e0209865. doi:10.1371/journal.pone.0209865

12. Ponce-de-león A, Camacho-Ortiz A, Macias AE, et al. Epidemiology and clinical characteristics of *Staphylococcus aureus* bloodstream infections in a tertiary-care center in Mexico City: 2003–2007. *Rev Invest Clin*. 2010;62:553–559.

13. Brakstad OG, Aasbak M, Kaeland JA. Detection of *Staphylococcus aureus* by polymerase chain reaction amplification of the nuc gene. *J Clin Microbiol*. 1992;30:1654–1660. doi:10.1128/JCM.30.7.1654-1660.1992

14. Relman DA. Universal bacterial 16S rDNA amplification and sequencing. In: Persing DH, Smith TF, Tenover FC, White TT, editors. *Diagnostic Molecular Microbiology: Principles and Applications*. Washington, DC: American Society of Microbiology; 1993:489–495.

15. Morgulis A, Coulouris G, Raytelsis Y, Madden TL, Agarwala R, Schäffer AA. Database Indexing for Production MegaBLAST Searches. *Bioinformatics*. 2008;24:1757–1764. doi:10.1093/bioinformatics/btn322

16. Zhang Z, Schwartz S, Wagner L, Miller W. A greedy algorithm for aligning DNA sequences. *J Comput Biol*. 2000;7(1–2):203–214. doi:10.1089/10665270050081478

17. CLSI. *Performance Standard for Antimicrobial Susceptibility Testing*. 30th. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2019

18. Louie L, Goodfellow J, Mathieu P, Glatt A, Louis M, Simor AE. Rapid detection of methicillin-resistant *staphylococci* from blood culture bottles by using a multiplex PCR assay. *J Clin Microbiol*. 2002;40:2786–2790. doi:10.1128/JCM.40.8.2786-2790.2002

19. Miele A, Bander A, Goldstein BG. Use of primers selective for vancomycin resistance genes to determine van type in enterococci and to study gene organization in VanA isolates. *Antimicrob Agents Chemother*. 1995;39(8):1772–1778. doi:10.1128/AAC.39.8.1772

20. Boye K, Bartels MD, Andersen IS, Møller JA, Westh H. A new multiplex PCR for easy screening of methicillin-resistant *Staphylococcus aureus* SCCmec types I-V. *Clin Microbiol Infect*. 2007;13:725–727. doi:10.1111/j.1469-0691.2007.01720.x

21. Lina G, Piémont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin producing *Staphylococcus aureus* in primary skin infections and pneumonia. *Clin Infect Dis*. 1999;29:1128–1132. doi:10.1086/313461

22. Azimian A, Fazeli H, Naderi M, et al. Genetic characterization of a vancomycin-resistant *Staphylococcus aureus* isolate form the respiratory tract of a patient in a university hospital in northeastern Iran. *J Clin Microbiol*. 2012;50:3581–3585. doi:10.1128/JCM.01727-12

23. Eftekhari F, Rezaee R, Azad M, Azimi H, Goudarzi H, Goudarzi M. Distribution of adhesion and toxin genes in *Staphylococcus aureus* strains recovered from hospitalized patients admitted to the UCI. *Arch Pediatr Infect Dis*. 2017;5:39349.
Infection and Drug Resistance

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use.

Submit your manuscript here: https://www.dovepress.com/infection-and-drug-resistance-journal

Infection and Drug Resistance 2021:14